{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T07:11:45Z","timestamp":1785222705507,"version":"3.55.0"},"reference-count":96,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myeloproliferative neoplasms (MPNs) are clonal disorders of the hematopoietic stem cell. Classical BCR\/ABL-negative MPNs include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Thrombotic events are a major cause of morbidity and mortality in these patients. Pathogenesis of blood clotting activation involves various abnormalities of platelets, erythrocytes, and leukocytes, as well as dysfunctions of endothelial cells. Patients with MPN can be stratified in \u201chigh risk\u201d or \u201clow risk\u201d of thrombosis according to established risk factors. ET and PV clinical management is highly dependent on the patient's thrombotic risk, and a risk-oriented management strategy to treat these diseases is strongly recommended. In this review, we give an overview of risk factors, pathogenesis, and thrombosis prevention and treatment in MPN.<\/jats:p>","DOI":"10.1055\/a-1334-3259","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T19:17:35Z","timestamp":1613503055000},"page":"048-057","source":"Crossref","is-referenced-by-count":16,"title":["Prevention and Management of Thrombosis in BCR\/ABL-Negative Myeloproliferative Neoplasms"],"prefix":"10.1055","volume":"41","author":[{"given":"Anna","family":"Falanga","sequence":"additional","affiliation":[{"name":"Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy"},{"name":"University of Milano-Bicocca, Department of Medicine and Surgery, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Marchetti","sequence":"additional","affiliation":[{"name":"Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Schieppati","sequence":"additional","affiliation":[{"name":"Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"issue":"20","key":"ref1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"D A Arber","year":"2016","journal-title":"Blood"},{"issue":"13","key":"ref2","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"T Barbui","year":"2013","journal-title":"Blood"},{"issue":"05","key":"ref3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study","volume":"168","author":"M Hultcrantz","year":"2018","journal-title":"Ann Intern Med"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12885-019-5387-9","article-title":"A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms","volume":"19","author":"T Rungjirajittranon","year":"2019","journal-title":"BMC Cancer"},{"issue":"19","key":"ref5","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","article-title":"In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology","volume":"124","author":"T Barbui","year":"2014","journal-title":"Blood"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"R Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"C N Harrison","year":"2005","journal-title":"N Engl J Med"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: incidence and risk factors","volume":"115","author":"T Barbui","year":"2010","journal-title":"Blood"},{"issue":"08","key":"ref9","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1182\/blood-2008-04-153783","article-title":"Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia","volume":"112","author":"A Carobbio","year":"2008","journal-title":"Blood"},{"issue":"11","key":"ref10","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3324\/haematol.13346","article-title":"Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients","volume":"93","author":"F Passamonti","year":"2008","journal-title":"Haematologica"},{"issue":"23","key":"ref11","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"T Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/s-0034-1370794","article-title":"Thrombosis in myeloproliferative neoplasms","volume":"40","author":"A Falanga","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/bjh.12461","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms","volume":"162","author":"M Sekhar","year":"2013","journal-title":"Br J Haematol"},{"issue":"09","key":"ref14","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"A Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"22","key":"ref15","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"A Carobbio","year":"2011","journal-title":"Blood"},{"issue":"06","key":"ref16","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"T Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management","volume":"95","author":"A Tefferi","year":"2020","journal-title":"Am J Hematol"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative neoplasms: a contemporary review","volume":"1","author":"A Tefferi","year":"2015","journal-title":"JAMA Oncol"},{"issue":"09","key":"ref19","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3324\/haematol.12970","article-title":"Effect of JAK2\u2009V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain","volume":"93","author":"P D Ziakas","year":"2008","journal-title":"Haematologica"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.leukres.2008.06.006","article-title":"Is JAK2\u2009V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia","volume":"33","author":"I J Dahabreh","year":"2009","journal-title":"Leuk Res"},{"issue":"25","key":"ref21","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"T Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"ref22","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"G Rotunno","year":"2014","journal-title":"Blood"},{"issue":"10","key":"ref23","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"E Rumi","year":"2014","journal-title":"Blood"},{"issue":"16","key":"ref24","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1182\/blood-2014-08-596676","article-title":"Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia","volume":"124","author":"G Finazzi","year":"2014","journal-title":"Blood"},{"issue":"09","key":"ref25","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.mayocp.2015.05.014","article-title":"Essential thrombocythemia and polycythemia vera: focus on clinical practice","volume":"90","author":"A Tefferi","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(78)92098-6","article-title":"Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia","volume":"2","author":"T C Pearson","year":"1978","journal-title":"Lancet"},{"issue":"02","key":"ref27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2006.06430.x","article-title":"The haematocrit and platelet target in polycythemia vera","volume":"136","author":"M Di Nisio","year":"2007","journal-title":"Br J Haematol"},{"issue":"04","key":"ref28","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3324\/haematol.2018.210732","article-title":"Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis","volume":"104","author":"V R Gordeuk","year":"2019","journal-title":"Haematologica"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"R Marchioli","year":"2013","journal-title":"N Engl J Med"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3324\/haematol.2016.152769","article-title":"Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea","volume":"102","author":"A Alvarez-Larr\u00e1n","year":"2017","journal-title":"Haematologica"},{"issue":"17","key":"ref31","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"S Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.beha.2005.07.011","article-title":"Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention","volume":"19","author":"R Landolfi","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"issue":"06","key":"ref33","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","volume":"109","author":"R Landolfi","year":"2007","journal-title":"Blood"},{"issue":"02","key":"ref34","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ajh.21614","article-title":"Leukocytosis as a risk factor for thrombosis in myeloproliferative neoplasms-biologically plausible but clinically uncertain","volume":"85","author":"A Tefferi","year":"2010","journal-title":"Am J Hematol"},{"issue":"04","key":"ref35","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2010.5","article-title":"Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients","volume":"24","author":"F Girodon","year":"2010","journal-title":"Leukemia"},{"issue":"12","key":"ref36","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41408-017-0035-6","article-title":"Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients","volume":"7","author":"S Cerquozzi","year":"2017","journal-title":"Blood Cancer J"},{"issue":"11","key":"ref37","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/bloodadvances.2019000211","article-title":"Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis","volume":"3","author":"A Carobbio","year":"2019","journal-title":"Blood Adv"},{"issue":"02","key":"ref38","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ajh.23895","article-title":"Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management","volume":"90","author":"A Tefferi","year":"2015","journal-title":"Am J Hematol"},{"issue":"26","key":"ref39","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"T Barbui","year":"2012","journal-title":"Blood"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia","volume":"5","author":"T Barbui","year":"2015","journal-title":"Blood Cancer J"},{"issue":"01","key":"ref41","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.2018.195321","article-title":"Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression","volume":"104","author":"A Guy","year":"2019","journal-title":"Haematologica"},{"issue":"05","key":"ref42","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"K I Ataga","year":"2017","journal-title":"N Engl J Med"},{"issue":"02","key":"ref43","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2012-01-404889","article-title":"Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation","volume":"121","author":"V Rosti","year":"2013","journal-title":"Blood"},{"issue":"01","key":"ref44","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajh.23590","article-title":"Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia","volume":"89","author":"M Marchetti","year":"2014","journal-title":"Am J Hematol"},{"issue":"10","key":"ref45","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1182\/blood-2008-06-164087","article-title":"Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera","volume":"112","author":"M Marchetti","year":"2008","journal-title":"Blood"},{"issue":"02","key":"ref46","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"R Landolfi","year":"2004","journal-title":"N Engl J Med"},{"issue":"09","key":"ref47","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","article-title":"Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years","volume":"90","author":"Y Najean","year":"1997","journal-title":"Blood"},{"issue":"07","key":"ref48","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V89.7.2319","article-title":"Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age","volume":"89","author":"Y Najean","year":"1997","journal-title":"Blood"},{"issue":"01","key":"ref49","first-page":"17","article-title":"From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera","volume":"34","author":"S M Fruchtman","year":"1997","journal-title":"Semin Hematol"},{"issue":"07","key":"ref50","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"G Finazzi","year":"2005","journal-title":"Blood"},{"issue":"05","key":"ref51","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"A M Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"01","key":"ref52","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"F Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"issue":"03","key":"ref53","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S2352-3026(19)30207-8","article-title":"Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study","volume":"7","author":"J-J Kiladjian","year":"2020","journal-title":"Lancet Haematol"},{"issue":"03","key":"ref54","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"H Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"issue":"12","key":"ref55","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s00277-014-2152-7","article-title":"Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea","volume":"93","author":"A Alvarez-Larr\u00e1n","year":"2014","journal-title":"Ann Hematol"},{"issue":"02","key":"ref56","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.2019004596","article-title":"A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia","volume":"136","author":"B Rocca","year":"2020","journal-title":"Blood"},{"issue":"10","key":"ref57","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"H Gisslinger","year":"2013","journal-title":"Blood"},{"issue":"01","key":"ref58","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3324\/haematol.2017.174672","article-title":"Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study","volume":"103","author":"G Birgeg\u00e5rd","year":"2018","journal-title":"Haematologica"},{"issue":"18","key":"ref59","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea","volume":"134","author":"A Yacoub","year":"2019","journal-title":"Blood"},{"issue":"02","key":"ref60","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1056\/NEJMc1401255","article-title":"Interferon alfa therapy in CALR-mutated essential thrombocythemia","volume":"371","author":"B Cassinat","year":"2014","journal-title":"N Engl J Med"},{"issue":"24","key":"ref61","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","article-title":"Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis","volume":"129","author":"P Guglielmelli","year":"2017","journal-title":"Blood"},{"issue":"60","key":"ref62","doi-asserted-by":"crossref","first-page":"101735","DOI":"10.18632\/oncotarget.21594","article-title":"Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria","volume":"8","author":"E Rumi","year":"2017","journal-title":"Oncotarget"},{"issue":"07","key":"ref63","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/ajh.23217","article-title":"Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early\/prefibrotic myelofibrosis: an international study of 264 patients","volume":"87","author":"V Buxhofer-Ausch","year":"2012","journal-title":"Am J Hematol"},{"issue":"01","key":"ref64","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/bjh.14202","article-title":"Impact of white blood cell counts at diagnosis and during follow-up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis","volume":"179","author":"V Buxhofer-Ausch","year":"2017","journal-title":"Br J Haematol"},{"issue":"04","key":"ref65","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/leu.2011.258","article-title":"Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria","volume":"26","author":"G Finazzi","year":"2012","journal-title":"Leukemia"},{"issue":"18","key":"ref66","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.2008.20.3174","article-title":"Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy","volume":"27","author":"P J Campbell","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"ref67","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-018-0142-z","article-title":"Prefibrotic myelofibrosis: treatment algorithm 2018","volume":"8","author":"G Finazzi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"03","key":"ref68","first-page":"178","article-title":"Prevention and management of thrombosis in myeloproliferative neoplasms","volume":"15","author":"M Sekhar","year":"2017","journal-title":"Clin Adv Hematol Oncol"},{"issue":"03","key":"ref69","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.12053","article-title":"Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments","volume":"93","author":"V De Stefano","year":"2008","journal-title":"Haematologica"},{"issue":"10","key":"ref70","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/leu.2016.85","article-title":"High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists","volume":"30","author":"V De Stefano","year":"2016","journal-title":"Leukemia"},{"issue":"06","key":"ref71","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00277-015-2330-2","article-title":"Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia","volume":"94","author":"J C Hern\u00e1ndez-Boluda","year":"2015","journal-title":"Ann Hematol"},{"issue":"08","key":"ref72","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-019-0225-5","article-title":"Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: a consensus-based position paper","volume":"9","author":"T Barbui","year":"2019","journal-title":"Blood Cancer J"},{"issue":"26","key":"ref73","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"R Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"issue":"09","key":"ref74","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"G Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"15","key":"ref75","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"H R B\u00fcller","year":"2013","journal-title":"N Engl J Med"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"C Kearon","year":"2012","journal-title":"Chest"},{"issue":"01","key":"ref77","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s11239-017-1566-1","article-title":"High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation","volume":"45","author":"R Castelli","year":"2018","journal-title":"J Thromb Thrombolysis"},{"issue":"02","key":"ref78","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3324\/haematol.10516","article-title":"The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients","volume":"92","author":"P Prandoni","year":"2007","journal-title":"Haematologica"},{"issue":"02","key":"ref79","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"A Y Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"07","key":"ref80","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"A YY Lee","year":"2015","journal-title":"JAMA"},{"issue":"07","key":"ref81","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41408-018-0100-9","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018","volume":"8","author":"G Finazzi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"07","key":"ref82","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"G E Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"ref83","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"A M Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"ref84","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"G Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"07","key":"ref85","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1055\/s-0040-1712098","article-title":"Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis","volume":"120","author":"M Giustozzi","year":"2020","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref86","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/1074248415575154","article-title":"Case fatality rates of recurrent thromboembolism and bleeding in patients receiving direct oral anticoagulants for the initial and extended treatment of venous thromboembolism: a systematic review","volume":"20","author":"A G\u00f3mez-Outes","year":"2015","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"08","key":"ref87","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1016\/S2352-3026(16)30057-6","article-title":"Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial","volume":"3","author":"G E Raskob","year":"2016","journal-title":"Lancet Haematol"},{"issue":"04","key":"ref88","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s12185-017-2282-5","article-title":"Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms","volume":"106","author":"J C Ianotto","year":"2017","journal-title":"Int J Hematol"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","article-title":"Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry","volume":"9","author":"A Kaifie","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"03","key":"ref90","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1111\/bjh.16485","article-title":"Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm-associated venous thromboembolism in a large tertiary centre in the UK","volume":"189","author":"N Curto-Garcia","year":"2020","journal-title":"Br J Haematol"},{"issue":"12","key":"ref91","doi-asserted-by":"crossref","first-page":"E329","DOI":"10.1002\/ajh.25990","article-title":"A multicenter real-life study on anticoagulant treatment with direct oral anticoagulants in patients with Ph-negative myeloproliferative neoplasms","volume":"95","author":"A Serrao","year":"2020","journal-title":"Am J Hematol"},{"issue":"04","key":"ref92","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/blood-2012-07-440487","article-title":"JAK2V617F activates Lu\/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1\/Akt pathway","volume":"121","author":"M De Grandis","year":"2013","journal-title":"Blood"},{"issue":"09","key":"ref93","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1172\/JCI92077","article-title":"Platelet-RBC interaction mediated by FasL\/FasR induces procoagulant activity important for thrombosis","volume":"128","author":"C Klatt","year":"2018","journal-title":"J Clin Invest"},{"issue":"02","key":"ref94","first-page":"169","article-title":"Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status","volume":"91","author":"E Arellano-Rodrigo","year":"2006","journal-title":"Haematologica"},{"issue":"10","key":"ref95","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1172\/JCI90312","article-title":"JAK2-V617F promotes venous thrombosis through \u03b21\/\u03b22 integrin activation","volume":"128","author":"B Edelmann","year":"2018","journal-title":"J Clin Invest"},{"issue":"436","key":"ref96","doi-asserted-by":"crossref","first-page":"eaan8292","DOI":"10.1126\/scitranslmed.aan8292","article-title":"Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms","volume":"10","author":"O Wolach","year":"2018","journal-title":"Sci Transl Med"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1334-3259.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T08:33:45Z","timestamp":1724488425000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1334-3259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":96,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2021,2,15]]},"published-print":{"date-parts":[[2021,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1334-3259","relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}